# Title

 Food and Drugs. PART 862â€”CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 862


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'prior to', 'more than', 'less than or equal to', 'lesser', 'after', 'minimum of', 'minimum', 'greater', 'at least']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Duration    | ['20.0 day', '21.0 year']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Condition   | ['until', 'unless', 'where', 'subject to', 'when', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Entities    | ['Estriol', 'Histidine', 'Alanine', 'Newborn', 'Such', 'Atomic', 'Androsterone', 'Test', 'Kanamycin', 'Lysergic', 'Triose', 'Creatinine', 'Lidocaine', 'Acid', 'Creatine', 'Amphetamine', 'Etiocholanolone', 'Magnesium', 'Alcohol', 'Vanilmandelic', 'Propoxyphene', 'Mercury', 'Dehydroepiandrosterone', 'Lactate', 'Food', 'Calcium', 'Parathyroid', 'Triglyceride', 'Microtitrator', 'Mucopolysaccharide', 'Neuroleptic', 'Ornithine', 'Particular', 'Methylmalonic', 'Tacrolimus', 'Triiodothyronine', 'Sirolimus', 'Lipoprotein', 'Antimony', 'Adrostenedione', 'Cystine', 'Corticosterone', 'Cholylglycine', 'Ureanitrogen', 'Class', 'Glucose', 'Glucagon', 'Sorbitol', 'Morphine', 'Fluorescence', 'Industry', 'Chromatographic', 'Folic', 'Blood', 'Globulin', 'Osmolality', 'Copper', 'Amikacin', 'Beta', 'Quinine', 'Hydroxybutyric', 'Ascorbic', 'Cardiac', 'Chloride', 'Nitrite', 'Scope', 'Thyroid', 'Protein', 'Drug', 'Phospholipid', 'Calibrator', 'Malic', 'Organophosphate', 'Gentamicin', 'Corticoids', 'Salicylate', 'Chymotrypsin', 'Device', 'Calcitonin', 'Sulfonamide', 'Centrifugal', 'Cyclosporine', 'U.S', 'Colorimeter', 'Digitoxin', 'Aldosterone', 'Amylase', 'Iron', 'Biotinidase', 'Percent', 'Electrophoresis', 'Galactose', 'Data', 'Lipase', 'Total', 'Sodium', 'Lithium', 'Acetaminophen', 'Opiate', 'Potassium', 'Digoxin', 'Ketones', 'Methadone', 'Codeine', 'Prolactin', 'Porphobilinogen', 'Diphenylhydantoin', 'Enzyme', 'Cannabinoid', 'Cushing', 'Benzodiazepine', 'Isocitric', 'Fatty', 'Aspartate', 'Gastric', 'Uroporphyrin', 'Free', 'Adrenocorticotropic', 'Micro', 'Estradiol', 'Uric', 'United States', 'True', 'Pseudo', 'Phosphohexose', 'Estrogens', 'Alkaline', 'High', 'Vancomycin', 'Bilirubin', 'Mucopolysaccharides', 'Porphyrins', 'Estrone', 'Leucine', 'Catecholamine', 'Tobramycin', 'Formiminoglutamic', 'Oxalate', 'Lysozyme', 'Lipid', 'Mass', 'Phenothiazine', 'Lecithin', 'Gas', 'Gastrin', 'FIGLU', 'Clinical', 'Plasma', 'Flame', 'Trypsin', 'Primidone', 'Methaqualone', 'Industry and FDA', 'Human', 'Aldolase', 'Discrete', 'Glutathione', 'Phenobarbital', 'Abnormal', 'Angiotensin', 'Osmotic', 'Hydroxyproline', 'Phenylalanine', 'Tricyclic', 'Cortisol', 'Lactic', 'Carbon', 'Phosphorus', 'Ammonia', 'Cholesterol', 'Guidance', 'Nitrogen'] |
| Date        | ['2018-03-03', '2018-02-01', '2018-02-03', '2018-01-25', '1976-05-28', '2018-03-01']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |


# Structured Analysis With Context

 


## Constraints

| Constraints           | Context                                                                                                                        |
|:----------------------|:-------------------------------------------------------------------------------------------------------------------------------|
| after                 | III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the          |
| before                | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                   |
| before                | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                   |
| after                 | the grace period ending on the 90th day after its promulgation or on the last day of                                           |
| after                 | the grace period ending on the 90th day after its promulgation or on the last day of                                           |
| after                 | equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed      |
| before                | or declaring completed a PDP for the device before the device is commercially distributed unless it is                         |
| before                | an approval under section 515 of the act before  commercial distribution.                                                      |
| within                | or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of      |
| before                | must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce   |
| before                | under section 515 of the act is required before the device described in paragraph (b)(1) may be                                |
| minimum               | Performance testing of device precision must, at a minimum , use blood samples with concentrations near 5.0                    |
| minimum of            | This testing must evaluate precision over a  minimum of 20 days using at least three lots of                                   |
| at least              | precision over a minimum of 20 days using at least three lots of the device and three instruments,                             |
| minimum of            | Performance testing of device accuracy must include a minimum of 120 blood samples that span the measuring interval            |
| less than or equal to | and this evaluation must demonstrate a total error less than or equal to  6 percent.                                           |
| lesser                | acute leukemias and megaloblastic anemias) and, to a lesser  degree, liver disease.                                            |
| prior to              | and to separate serum from nonserum (cellular) components prior to  further testing.                                           |
| minimum               | Performance testing of device precision must, at a minimum , use intended sample type with Vitamin D                           |
| at least              | precision studies must be an unmodified patient sample. at least                                                               |
| minimum of            | Performance testing of device accuracy must include a minimum of 115 serum or plasma samples that span the                     |
| at least              | collected from apparently healthy male and female adults at least  21 years of age and older from                              |
| at least              | collected from apparently healthy male and female adults at least  21 years of age and older from                              |
| within                | older from at least 3 distinct climatic regions within  the United States in different weather seasons.                        |
| at least              | The well-characterized sample panel shall include samples from  at least two sources that have highly confident sequence based |
| at least              | the manufacturer with respect to technology and analysis. at least                                                             |
| before                | serum, urine, cerebrospinal fluid, and other body fluids  before  the fluids are analyzed.                                     |
| more than             | Such instrumentation may be compatible with  more than  one specific assay.                                                    |
| lesser                | prevent the passage of a solution with a lesser solute concentration into a solution with greater solute                       |
| greater               | a lesser solute concentration into a solution with greater solute concentration when the two solutions are separated           |


## Duration

| Duration   | Context                                                                                                                                                                                                                                |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20.0 day   | This testing must evaluate precision over a minimum of 20 days using at least three lots of the device and three instruments, as applicable.                                                                                           |
| 21.0 year  | The study must be conducted using samples collected from apparently healthy male and female adults at least 21 years of age and older from at least 3 distinct climatic regions within the United States in different weather seasons. |


## Condition

| Condition   | Context                                                                                                                 |
|:------------|:------------------------------------------------------------------------------------------------------------------------|
| subject to  | of every device that is, or will be, subject to  the regulation.                                                        |
| unless      | Regulations are to chapter I of title 21 unless  otherwise noted.                                                       |
| if          | a device and its calibrator may have d if ferent class                                                                  |
| unless      | date shown in the regulation classifying the device unless the manufacturer has an approval under section 515           |
| unless      | Accordingly,  unless an effective date of the requirement for premarket                                                 |
| unless      | the device before the device is commercially distributed unless  it is reclassified.                                    |
| where       | or the device is intended for lay use where the former intended use was by health care                                  |
| when        | into interstate commerce for commercial distribution the device when : (a) The device is intended for a                 |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| if          | normal and abnormal distruction of red blood cells, if used in the diagnosis and treatment of liver,                    |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| if          | is not a continuous glucose monitor secondary display if the data from the primary display device is                    |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to the limitations in &#167;&#8201;862.9 Human growth hormone test        |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| when        | devices describing the interference and any affected populations. when                                                  |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| if          | The ident if ication of methylmalonic acid in urine is used                                                             |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| if          | the diagnosis and treatment of congenital phenylketonuria which, if  untreated, may cause mental retardation.           |
| if          | The ident if ication of urinary phenylketones is used in the                                                            |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| when        | Except  when used in donor screening tests, unassayed material is                                                       |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | notification procedures in subpart E of part 807 subject to  the limitations in &#167;&#8201;862.9.                     |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | notification procedures in subpart E of part 807 subject to  the limitations in &#167;&#8201;862.9.                     |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| if          | substances that may interfere with the instrument system. if                                                            |
| if          | accurate result for a given sample across d if ferent indexing primer combinations.                                     |
| until       | eluted off by a moving solvent (moving phase) until  equilibrium occurs between the two phases.                         |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| when        | is the property of certain substances of radiating, when  illuminated, a light of a different wavelength.               |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| when        | concentration into a solution with greater solute concentration when the two solutions are separated by a semipermeable |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| when        | and intensity of the light that is absorbed when the specimen is converted to the atomic vapor                          |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;862.9.                                |
| when        | Except  when used in donor screening, unassayed material is exempt                                                      |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;862.9.                                                   |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;862.9.                               |


## Entities

| Entities               | Context                                                                                                                                              |
|:-----------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                   | Food  and Drugs.                                                                                                                                     |
| Scope                  | Scope .                                                                                                                                              |
| Acid                   | Acid  phosphatase (total or prostatic) test system.                                                                                                  |
| Adrenocorticotropic    | Adrenocorticotropic  hormone (ACTH) test system.                                                                                                     |
| Cushing                | certain disorders of the adrenal glands such as Cushing 's syndrome, adrenocortical insufficiency, and the ectopic ACTH                              |
| Alanine                | Alanine  amino transferase (ALT/SGPT) test system.                                                                                                   |
| Alanine                | Alanine amino transferase measurements are used in the diagnosis                                                                                     |
| Aldolase               | Aldolase  test system.                                                                                                                               |
| Aldolase               | Aldolase measurements are used in the diagnosis and treatment                                                                                        |
| Aldosterone            | Aldosterone measurements are used in the diagnosis and treatment                                                                                     |
| Alkaline               | Alkaline  phosphatase or isoenzymes test system.                                                                                                     |
| Newborn                | Newborn screening test system for amino acids, free carnitine,                                                                                       |
| Ammonia                | Ammonia  test system.                                                                                                                                |
| Ammonia                | measure ammonia levels in blood, serum, and plasma, Ammonia measurements are used in the diagnosis and treatment                                     |
| Amylase                | Amylase measurements are used primarily for the diagnosis and                                                                                        |
| Adrostenedione         | Adrostenedione measurements are used in the diagnosis and treatment                                                                                  |
| Androsterone           | Androsterone measurements are used in the diagnosis and treatment                                                                                    |
| Angiotensin            | Angiotensin  converting enzyme (A.C.E.)                                                                                                              |
| Ascorbic               | Ascorbic  acid test system.                                                                                                                          |
| Ascorbic               | Ascorbic acid measurements are used in the diagnosis and                                                                                             |
| Aspartate              | Aspartate  amino transferase (AST/SGOT) test system.                                                                                                 |
| Aspartate              | Aspartate amino transferase measurements are used in the diagnosis                                                                                   |
| Bilirubin              | Bilirubin  (total or direct) test system.                                                                                                            |
| Bilirubin              | Bilirubin  (total and unbound) in the neonate test system.                                                                                           |
| Industry               | B-Type Natriuretic Peptide Premarket Notifications; Final Guidance for Industry  and FDA Reviewers.&#8221;                                           |
|                        |               Biotinidase test system.                                                                                                               |
| Biotinidase            | Notifications; Final Guidance for Industry and FDA Reviewers.&#8221; Biotinidase  test system.                                                       |
| Blood                  | Blood  gases (P (a) Identification.                                                                                                                  |
| Blood                  | Blood  volume test system.                                                                                                                           |
| Blood                  | Blood volume measurements are used in the diagnosis and                                                                                              |
| Calcitonin             | Calcitonin  test system.                                                                                                                             |
| Calcitonin             | Calcitonin measurements are used in the diagnosis and treatment                                                                                      |
| Calcium                | Calcium  test system.                                                                                                                                |
| Calcium                | Calcium measurements are used in the diagnosis and treatment                                                                                         |
| Calibrator             | Calibrator .                                                                                                                                         |
| Human                  | Human  chorionic gonadotropin (HCG) test system.                                                                                                     |
| Cardiac                | Cardiac  allograft gene expression profiling test system.                                                                                            |
| Catecholamine          | Catecholamine determinations are used in the diagnosis and treatment                                                                                 |
| Chloride               | Chloride  test system.                                                                                                                               |
| Chloride               | Chloride measurements are used in the diagnosis and treatment                                                                                        |
| Cholesterol            | Cholesterol  (total) test system.                                                                                                                    |
| Cholesterol            | Cholesterol measurements are used in the diagnosis and treatment                                                                                     |
| Cholylglycine          | Cholylglycine  test system.                                                                                                                          |
| Chymotrypsin           | Chymotrypsin  test system.                                                                                                                           |
| Chymotrypsin           | Chymotrypsin measurements are used in the diagnosis and treatment                                                                                    |
| Copper                 | Copper  test system.                                                                                                                                 |
| Test                   | Test results are also used in monitoring patients with                                                                                               |
| Corticoids             | Corticoids  test system.                                                                                                                             |
| Corticosterone         | Corticosterone  test system.                                                                                                                         |
| Cortisol               | Cortisol  (hydrocortisone and hydroxycorticosterone) test system.                                                                                    |
| Creatine               | Creatine  test system.                                                                                                                               |
| Creatine               | Creatine  phosphokinase/creatine kinase or isoenzymes test system.                                                                                   |
| Test                   | Test results are intended to be used in conjunction                                                                                                  |
| Creatinine             | Creatinine  test system.                                                                                                                             |
| Creatinine             | Creatinine measurements are used in the diagnosis and treatment                                                                                      |
| Cyclosporine           | Cyclosporine  test system.                                                                                                                           |
| Guidance               | The special control is &#8220;Class II Special Controls  Guidance  Document: Cyclosporine and Tacrolimus Assays;                                     |
| Industry and FDA       | Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA .&#8221; See &#167;&#8201;862.1(d) for the availability of this |
| Cystine                | Cystine  test system.                                                                                                                                |
| Cystine                | Cystine measurements are used in the diagnosis of cystinuria                                                                                         |
| Dehydroepiandrosterone | Dehydroepiandrosterone  (free and sulfate) test system.                                                                                              |
| Dehydroepiandrosterone | Dehydroepiandrosterone measurements are used in the diagnosis and treatment                                                                          |
| Estradiol              | Estradiol  test system.                                                                                                                              |
| Estradiol              | Estradiol measurements are used in the diagnosis and treatment                                                                                       |
| Estriol                | Estriol  test system.                                                                                                                                |
| Estriol                | Estriol measurements are used in the diagnosis and treatment                                                                                         |
| Estrogens              | Estrogens  (total, in pregnancy) test system.                                                                                                        |
| Estrogens              | Estrogens  (total, nonpregnancy) test system.                                                                                                        |
| Estrone                | Estrone measurements are used in the diagnosis and treatment                                                                                         |
| Etiocholanolone        | Etiocholanolone is a metabolic product of the hormone testosterone                                                                                   |
| Etiocholanolone        | Etiocholanolone measurements are used in the diagnosis and treatment                                                                                 |
| Fatty                  | Fatty  acids test system.                                                                                                                            |
| Folic                  | Folic  acid test system.                                                                                                                             |
| Folic                  | Folic acid measurements are used in the diagnosis and                                                                                                |
| Formiminoglutamic      | Formiminoglutamic  acid (FIGLU) test system.                                                                                                         |
| FIGLU                  | FIGLU measurements obtained by this device are used in                                                                                               |
| Galactose              | Galactose  test system.                                                                                                                              |
| Gastric                | Gastric  acidity test system.                                                                                                                        |
| Gastrin                | Gastrin  test system.                                                                                                                                |
| Globulin               | Globulin  test system.                                                                                                                               |
| Glucagon               | Glucagon  test system.                                                                                                                               |
| Glucagon               | Glucagon measurements are used in the diagnosis and treatment                                                                                        |
| Glucose                | Glucose  test system.                                                                                                                                |
| Glucose                | Glucose measurements are used in the diagnosis and treatment                                                                                         |
| Glutathione            | Glutathione  test system.                                                                                                                            |
| Glutathione            | Glutathione measurements are used in the diagnosis and treatment                                                                                     |
| Human                  | Human growth hormone measurements are used in the diagnosis                                                                                          |
| Histidine              | Histidine  test system.                                                                                                                              |
| Histidine              | Histidine measurements are used in the diagnosis and treatment                                                                                       |
| Hydroxybutyric         | Hydroxybutyric  dehydrogenase test system.                                                                                                           |
| Hydroxyproline         | Hydroxyproline  test system.                                                                                                                         |
| Hydroxyproline         | Hydroxyproline measurements are used in the diagnosis and treatment                                                                                  |
| Iron                   | Iron  (non-heme) test system.                                                                                                                        |
| Iron                   | Iron (non-heme) measurements are used in the diagnosis and                                                                                           |
| Isocitric              | Isocitric dehydrogenase measurements are used in the diagnosis and                                                                                   |
| Ketones                | Ketones  (nonquantitative) test system.                                                                                                              |
| Lactate                | Lactate  dehydrogenase test system.                                                                                                                  |
| Lactate                | Lactate dehydrogenase measurements are used in the diagnosis and                                                                                     |
| Lactate                | Lactate  dehydrogenase isoenzymes test system.                                                                                                       |
| Lactic                 | Lactic  acid test system.                                                                                                                            |
| Lactic                 | Lactic acid measurements that evaluate the acid-base status are                                                                                      |
| Lecithin               | Lecithin and sphingomyelin are phospholipids (fats or fat-like substances                                                                            |
| Leucine                | Leucine  aminopeptidase test system.                                                                                                                 |
| Leucine                | Leucine aminopeptidase measurements are used in the diagnosis and                                                                                    |
| Lipase                 | Lipase  test system.                                                                                                                                 |
| Lipase                 | Lipase measurements are used in diagnosis and treatment of                                                                                           |
| Lipid                  | Lipid  (total) test system.                                                                                                                          |
| Lipid                  | Lipid (total) measurements are used in the diagnosis and                                                                                             |
| Lipoprotein            | Lipoprotein  test system.                                                                                                                            |
| Lipoprotein            | Lipoprotein measurements are used in the diagnosis and treatment                                                                                     |
| Lysozyme               | Lysozyme  (muramidase) test system.                                                                                                                  |
| Lysozyme               | Lysozyme measurements are used in the diagnosis and treatment                                                                                        |
| Magnesium              | Magnesium  test system.                                                                                                                              |
| Magnesium              | Magnesium measurements are used in the diagnosis and treatment                                                                                       |
| Malic                  | Malic dehydrogenase measurements are used in the diagnosis and                                                                                       |
| Mucopolysaccharides    | Mucopolysaccharides  (nonquantitative) test system.                                                                                                  |
| Mucopolysaccharide     | Mucopolysaccharide measurements in urine are used in the diagnosis                                                                                   |
| Methylmalonic          | Methylmalonic  acid (nonquantitative) test system.                                                                                                   |
| Nitrite                | Nitrite  (nonquantitative) test system.                                                                                                              |
| Nitrite                | Nitrite identification is used in the diagnosis and treatment                                                                                        |
| Nitrogen               | Nitrogen  (amino-nitrogen) test system.                                                                                                              |
| Nitrogen               | Nitrogen (amino-nitrogen) measurements are used in the diagnosis and                                                                                 |
| Plasma                 | Plasma  oncometry test system.                                                                                                                       |
| Plasma                 | Plasma oncotic pressure is that portion of the total                                                                                                 |
| Ornithine              | Ornithine  carbamyl transferase test system.                                                                                                         |
| Ornithine              | Ornithine carbamyl transferase measurements are used in the diagnosis                                                                                |
| Osmolality             | Osmolality  test system.                                                                                                                             |
| Osmolality             | Osmolality measurement is used as an adjunct to other                                                                                                |
| Oxalate                | Oxalate  test system.                                                                                                                                |
| Parathyroid            | Parathyroid  hormone test system.                                                                                                                    |
| Phenylalanine          | Phenylalanine  test system.                                                                                                                          |
| Phosphohexose          | Phosphohexose  isomerase test system.                                                                                                                |
| Phospholipid           | Phospholipid  test system.                                                                                                                           |
| Phosphorus             | Phosphorus  (inorganic) test system.                                                                                                                 |
| Human                  | Human  placental lactogen test system.                                                                                                               |
| Porphobilinogen        | Porphobilinogen  test system.                                                                                                                        |
| Porphyrins             | Porphyrins  test system.                                                                                                                             |
| Potassium              | Potassium  test system.                                                                                                                              |
| Prolactin              | Prolactin  (lactogen) test system.                                                                                                                   |
| Protein                | Protein  (fractionation) test system.                                                                                                                |
| Protein                | Protein fractionations are used as an aid in recognizing                                                                                             |
| Total                  | Total  protein test system.                                                                                                                          |
| Sodium                 | Sodium  test system.                                                                                                                                 |
| Sorbitol               | Sorbitol  dehydrogenase test system.                                                                                                                 |
| Blood                  | Blood  specimen collection device.                                                                                                                   |
| Tacrolimus             | Tacrolimus  test system.                                                                                                                             |
| Guidance               | The special control is &#8220;Class II Special Controls  Guidance  Document: Cyclosporine and Tacrolimus Assays;                                     |
| Industry and FDA       | Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA .&#8221; See &#167;&#8201;862.1(d) for the availability of this |
| Thyroid                | Thyroid  stimulating hormone test system.                                                                                                            |
| Free                   | Free  thyroxine test system.                                                                                                                         |
| Total                  | Total  thyroxine test system.                                                                                                                        |
| Triglyceride           | Triglyceride  test system.                                                                                                                           |
| Total                  | Total  triiodothyronine test system.                                                                                                                 |
| Triiodothyronine       | Triiodothyronine  uptake test system.                                                                                                                |
| Triose                 | Triose  phosphate isomerase test system.                                                                                                             |
| Triose                 | Triose phosphate isomerase is an enzyme important in glycolysis                                                                                      |
| Trypsin                | Trypsin  test system.                                                                                                                                |
| Free                   | Free  tyrosine test system.                                                                                                                          |
| Ureanitrogen           | Urea nitrogen test system. Ureanitrogen                                                                                                              |
| Uric                   | Uric  acid test system.                                                                                                                              |
| Uroporphyrin           | Uroporphyrin  test system.                                                                                                                           |
| Vanilmandelic          | Vanilmandelic  acid test system.                                                                                                                     |
| Total                  | Total  25-hydroxyvitamin D mass spectrometry test system.                                                                                            |
| United States          | at least 3 distinct climatic regions within the United States  in different weather seasons.                                                         |
| U.S                    | this study population must be representative of the U.S . population demographics.                                                                   |
| Centrifugal            | Centrifugal  chemistry analyzer for clinical use.                                                                                                    |
| Discrete               | Discrete  photometric chemistry analyzer for clinical use.                                                                                           |
| Micro                  | Micro  chemistry analyzer for clinical use.                                                                                                          |
| Chromatographic        | Chromatographic  separation material for clinical use.                                                                                               |
| Gas                    | Gas  liquid chromatography system for clinical use.                                                                                                  |
| High                   | High  pressure liquid chromatography system for clinical use.                                                                                        |
| High                   | High  throughput genomic sequence analyzer for clinical use.                                                                                         |
| Device                 | Device results shall be compared to reference sequence data                                                                                          |
| Percent                | Percent agreement and percent disagreement with the reference sequences                                                                              |
| Data                   | Data  supporting such claims must also be summarized.                                                                                                |
| Particular             | Particular components of TLC systems, i.e., the thin-layer chromatography                                                                            |
| Colorimeter            | Colorimeter , photometer, or spectrophotometer for clinical use.                                                                                     |
| Beta                   | Beta  or gamma counter for clinical use.                                                                                                             |
| Clinical               | Clinical samples are prepared by addition of a radioactive                                                                                           |
| Electrophoresis        | Electrophoresis  apparatus for clinical use.                                                                                                         |
| Enzyme                 | Enzyme  analyzer for clinical use.                                                                                                                   |
| Flame                  | Flame  emission photometer for clinical use.                                                                                                         |
| Abnormal               | Abnormal variations in the concentration of these substances in                                                                                      |
| Fluorescence           | Fluorescence is the property of certain substances of radiating,                                                                                     |
| Such                   | Such instrumentation may be compatible with more than one                                                                                            |
| Microtitrator          | Microtitrator  for clinical use.                                                                                                                     |
| Plasma                 | Plasma  oncometer for clinical use.                                                                                                                  |
| Osmotic                | Osmotic pressure is the pressure required to prevent the                                                                                             |
| Atomic                 | Atomic  absorption spectrophotometer for clinical use.                                                                                               |
| Mass                   | Mass  spectrometer for clinical use.                                                                                                                 |
| Plasma                 | Plasma  viscometer for clinical use.                                                                                                                 |
| Acetaminophen          | Acetaminophen  test system.                                                                                                                          |
| Amikacin               | Amikacin  test system.                                                                                                                               |
| Alcohol                | Alcohol  test system.                                                                                                                                |
| Amphetamine            | Amphetamine  test system.                                                                                                                            |
| Antimony               | Antimony  test system.                                                                                                                               |
| Benzodiazepine         | Benzodiazepine  test system.                                                                                                                         |
| Carbon                 | Carbon  monoxide test system.                                                                                                                        |
| True                   | True cholinesterase is present at nerve endings and in                                                                                               |
| Pseudo                 | Pseudo cholinesterase is present in plasma and liver but                                                                                             |
| Codeine                | Codeine  test system.                                                                                                                                |
| Digitoxin              | Digitoxin  test system.                                                                                                                              |
| Digoxin                | Digoxin  test system.                                                                                                                                |
| Diphenylhydantoin      | Diphenylhydantoin  test system.                                                                                                                      |
| Drug                   | Drug  metabolizing enzyme genotyping system.                                                                                                         |
| Gentamicin             | Gentamicin  test system.                                                                                                                             |
| Kanamycin              | Kanamycin  test system.                                                                                                                              |
| Lidocaine              | Lidocaine  test system.                                                                                                                              |
| Lithium                | Lithium  test system.                                                                                                                                |
| Lysergic               | Lysergic  acid diethylamide (LSD) test system.                                                                                                       |
| Mercury                | Mercury  test system.                                                                                                                                |
| Methadone              | Methadone  test system.                                                                                                                              |
| Methaqualone           | Methaqualone  test system.                                                                                                                           |
| Morphine               | Morphine  test system.                                                                                                                               |
| Neuroleptic            | Neuroleptic  drugs radioreceptor assay test system.                                                                                                  |
| Opiate                 | Opiate  test system.                                                                                                                                 |
| Organophosphate        | Organophosphate  test system.                                                                                                                        |
| Phenobarbital          | Phenobarbital  test system.                                                                                                                          |
| Phenothiazine          | Phenothiazine  test system.                                                                                                                          |
| Primidone              | Primidone  test system.                                                                                                                              |
| Propoxyphene           | Propoxyphene  test system.                                                                                                                           |
| Quinine                | Quinine  test system.                                                                                                                                |
| Class                  | Class  I.                                                                                                                                            |
|                        |               Reagents for molecular diagnostic instrument test systems.                                                                             |
| Salicylate             | Salicylate  test system.                                                                                                                             |
| Sirolimus              | Sirolimus  test system.                                                                                                                              |
| Sulfonamide            | Sulfonamide  test system.                                                                                                                            |
| Cannabinoid            | Cannabinoid  compounds include delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene.                                           |
| Tobramycin             | Tobramycin  test system.                                                                                                                             |
| Tricyclic              | Tricyclic  antidepressant drugs test system.                                                                                                         |
| Vancomycin             | Vancomycin  test system.                                                                                                                             |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified.                               |
| 1976-05-28 | Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.                                                                                                                                                                                                                                                                     |
| 1976-05-28 | As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed.                                                                                                                                                                                                                                                                                                 |
| 2018-02-03 | 2,3-Diphosphoglyceric acid test system.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 2018-02-03 | A 2,3-diphosphoglyceric acid test system is a device intended to measure 2,3-diphosphoglyceric acid (2,3-DPG) in erythrocytes (red blood cells).                                                                                                                                                                                                                                                                                                                                                |
| 2018-02-03 | A 2,3-diphosphoglyceric acid test system is a device intended to measure 2,3-diphosphoglyceric acid (2,3-DPG) in erythrocytes (red blood cells).                                                                                                                                                                                                                                                                                                                                                |
| 2018-02-03 | A 2,3-diphosphoglyceric acid test system is a device intended to measure 2,3-diphosphoglyceric acid (2,3-DPG) in erythrocytes (red blood cells).                                                                                                                                                                                                                                                                                                                                                |
| 2018-03-01 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |
| 2018-02-01 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |
| 2018-03-03 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |
| 2018-02-03 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |
| 2018-03-03 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |
| 2018-01-25 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |
| 2018-01-25 | (iii) Interference from vitamin D analogs and metabolites including vitamin D2, vitamin D3, 1-hydroxyvitamin D2, 1-hydroxyvitamin D3, 3-Epi-25-Hydroxyvitamin D2, 3-Epi-25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D2, 1,25-Dihydroxyvitamin D3, 3-Epi-1,25-Dihydroxyvitamin D2, and 3-Epi-1,25-Dihydroxyvitamin D3, 25, 26-Dihydroxyvitamin-D3, 24 (R), 25-dihydroxyvitamin-D3, 23 (R), 25-dihydroxyvitamin-D3 must be described in the 21 CFR 809.10(b)(7) compliant labeling of the device. |


